Pituitary function following peptide receptor radionuclide therapy for neuroendocrine tumours

Pituitary function following peptide receptor radionuclide therapy for neuroendocrine tumours

Abstract Peptide receptor radionuclide therapy (PRRT) is an increasingly used treatment for unresectable neuroendocrine tumours (NETs) that express somatostatin receptors. Normal pituitary tissue expresses somatostatin receptors so patients receiving PRRT may be at risk of developing hypopituitarism...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Marianne S. Elston, Amanda Love, Dev Kevat, Richard Carroll, Zhen Rong Siow, Sharon Pattison, Veronica Boyle, Eva Segelov, Andrew H. Strickland, David Wyld, Richard Gauci, Kim Kennedy, David Ransom, the Commonwealth Neuroendocrine Tumour Collaboration (CommNETs)
Formato: article
Lenguaje:EN
Publicado: Wiley 2021
Materias:
hypogonadism
hypopituitarism
neuroendocrine tumours
radioisotopes
receptor
somatostatin
Neoplasms. Tumors. Oncology. Including cancer and carcinogens
RC254-282
Acceso en línea:https://doaj.org/article/023c9ccd95dd41eba7390ebfa9e2d272
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Internet

https://doaj.org/article/023c9ccd95dd41eba7390ebfa9e2d272

Ejemplares similares